Kostarox

Etoricoxib, the active ingredient in Kostarox, is a COX-2 selective NSAID presented as an oral dosage form for oral use. It is indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and gout in adult patients. GNH USA supplies Kostarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kostarox (etoricoxib) is a COX‑2 selective NSAID used to treat several inflammatory and painful conditions. - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: alleviates synovial inflammation and pain. - Ankylosing spondylitis: decreases spinal inflammation and stiffness. - Acute pain: provides rapid relief of moderate to severe pain. - Gout: helps control pain and inflammation during acute gout attacks.

Etoricoxib may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Hypertension: increase in blood pressure readings. - Peripheral edema: swelling of the lower limbs. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction or stroke. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic impairment: elevated liver enzymes or hepatitis.

Before prescribing Kostarox, clinicians should consider several safety aspects. - Cardiovascular risk: assess history of heart disease or stroke. - Gastrointestinal history: evaluate prior ulcers or bleeding. - Renal function: monitor creatinine in patients with kidney disease. - Concomitant drugs: review use of anticoagulants, other NSAIDs or corticosteroids. - Pregnancy and lactation: avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Etoricoxib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened hemorrhage potential.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs, diuretics): possible reduction in blood‑pressure control. - Lithium: risk of lithium toxicity due to reduced renal clearance. - Methotrexate: potential for increased methotrexate levels.